DEA Approves MMJ Treatment Research For PTSD
The Drug Enforcement Agency, which is usually known for cracking down on cannabis, has approved a clinical trial to develop the marijuana plant into a prescription medicine to treat PTSD symptoms. The Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit organization dedicated to alternative medicine —will sponsor the controlled trial, documenting the effects of marijuana when smoked by war veterans suffering from chronic, treatment-resistant PTSD.
The research begin some time this year and will test four different strains. The strains will be analyzed and compared by dosage, composition, side effects, and different benefits between plants with varying levels of tetrahydrocannabinol (THC) and cannabidiol (CBD).
Federal agencies such as Food and Drug Administration (FDA), the National Institute on Drug Abuse (NIDA), and the Public Health Service (PHS), have also given the medical marijuana research the go-ahead. NIDA is to provide MAPS with the medical marijuana for research.
The U.S. Department of Veterans Affairs currently prohibits doctors from prescribing marijuana to patients, even in states where csnnabis is legal. Despite the significant amount of evidence that marijuana could help those suffering from PTSD, the Department of Veterans Affairs still states, "controlled studies have not been conducted to evaluate the safety or effectiveness of medical marijuana for PTSD."